Skip to main content

Coronavirus Update: Eli Lilly and Amgen to Manufacture Possible COVID-19 Drugs

Publish date:
Video Duration:

Good morning, it’s Thursday, Sept. 17. Here’s your daily coronavirus update.

According to Johns Hopkins, There are over 29.8 million cases of the virus worldwide, with over 941,000 deaths.

The U.S. has surpassed 6.6 million cases with 196,000 deaths.

Per the COVID-19 Tracking Project, there were 40,021 new cases reported Wednesday, which is higher than the 35,445 cases reported the day earlier. 665,622 new tests were reported. And 1,202 deaths were reported yesterday, which is higher than the 1,031 deaths reported the day prior.

Eli Lilly has reached an agreement with Amgen to manufacture its experimental COVID-19 antibody treatment.

This comes after Lilly released data yesterday that showed the drug, LY-CoV555 reduced the need for hospitalization and emergency-room visits among patients with moderate coronavirus.

The company said that LY-CoV555 was well-tolerated, and no drug-related serious adverse effects were reported.

The trial enrolled mild-to-moderate recently diagnosed COVID-19 patients across four groups.

reduced the need for hospitalization and emergency-room visits among patients with moderate coronavirus, according to interim data from a mid-stage clinical trial.

Eli Lilly said the rate of hospitalization and emergency-room visits was 1.7% for patients taking the drug, while the rate for patients taking the placebo was 6%.

Most patients, Eli Lilly said, including those receiving placebo, demonstrated near-complete viral clearance by the 11th day.

David Reese, Amgen’s research and development chief, said, “We are impressed with Lilly’s data, in particular the reduction in hospitalizations, and are enthusiastic about the potential for these neutralizing antibodies as a therapeutic for COVID-19.”

You can follow Katherine Ross on Twitter at @byKatherineRoss.

Read more from Katherine Ross here.

Watch More on the Coronavirus Pandemic From

Related Videos